Drug Profile
Immune globulin - ADMA Biologics
Alternative Names: ASCENIV; IGIV - ADMA Biologics; Immune globulin intravenous human - ADMA Biologics; Immune globulin intravenous, human – slra; Respiratory syncytial virus immune globulin - ADMA Biologics; RI-001; RI-002Latest Information Update: 15 Dec 2022
Price :
$50
*
At a glance
- Originator ADMA Biologics; Baylor College of Medicine
- Developer ADMA Biologics
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Immunodeficiency disorders
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 13 Dec 2022 US FDA approves of room temperature (25°C) storage for ASCENIV and BIVIGAM
- 28 Nov 2022 No recent reports of development identified for clinical-Phase-Unknown development in Respiratory-syncytial-virus-infections(In children) in USA (IV)
- 31 May 2022 ADMA Biologics has patent protection covering hyperimmune globulin for treating respiratory infections including those caused by respiratory syncytial virus, coronavirus, influenza virus, parainfluenza virus, and metapneumovirus in USA